Sublingual dexmedetomidine: repurposing an anesthetic as an anti-agitation agent

References

• Citrome L. Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents. Ther Clin Risk Manag. 2013;9:235–245.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association (Ed.). Diagnostic and statistical manual of mental disorders: DSM-5-TR. Fifth ed. Washington, DC: American Psychiatric Association Publishing; 2022.
   Google Scholar
• Nordstrom K, Allen MH. Alternative delivery systems for agents to treat acute agitation: progress to date. Drugs. 2013;73(16):1783–1792.
   PubMed Web of Science ®Google Scholar
• Garriga M, Pacchiarotti I, Kasper S, et al. Assessment and management of agitation in psychiatry: expert consensus. World J Biol Psychiatry. 2016;17(2):86–128.
   PubMed Web of Science ®Google Scholar
• Pompili M, Ducci G, Galluzzo A, et al. The Management of Psychomotor Agitation Associated with Schizophrenia or Bipolar Disorder: a Brief Review. Int J Environ Res Public Health. 2021;18(8):4368.
   PubMed Web of Science ®Google Scholar
• San L, Marksteiner J, Zwanzger P, et al. State of Acute Agitation at Psychiatric Emergencies in Europe: the STAGE Study. Clin Pract Epidemiol Ment Health. 2016;12(1):75–86.
   PubMedGoogle Scholar
• Miner JR, Klein LR, Cole JB, et al. The characteristics and prevalence of agitation in an Urban county emergency department. Ann Emerg Med. 2018;72(4):361–370.
   PubMed Web of Science ®Google Scholar
• Pascual JC, Madre M, Puigdemont D, et al. [A naturalistic study: 100 consecutive episodes of acute agitation in a psychiatric emergency department]. Actas Esp Psiquiatr. 2006;34(4):239–244.
   PubMed Web of Science ®Google Scholar
• Sachs GS. A review of agitation in mental illness: burden of illness and underlying pathology. J Clin Psychiatry. 2006;67(Suppl 10):5–12.
   PubMedGoogle Scholar
• Citrome L, Volavka J. Violent patients in the emergency setting. Psychiatr Clin North Am. 1999;22:789–801.
   PubMed Web of Science ®Google Scholar
• Rubio-Valera M, Luciano JV, Ortiz JM, et al. Health service use and costs associated with aggressiveness or agitation and containment in adult psychiatric care: a systematic review of the evidence. BMC Psychiatry. 2015;15:35.
   PubMed Web of Science ®Google Scholar
• Cots F, Chiarello P, Pérez V, et al. Hospital costs associated with agitation in the acute care setting. Psychiatr Serv. 2016;67:124–127.
   PubMed Web of Science ®Google Scholar
• Roppolo LP, Morris DW, Khan F, et al. Improving the management of acutely agitated patients in the emergency department through implementation of Project BETA (Best Practices in the Evaluation and Treatment of Agitation). J Am Coll Emerg Physicians Open. 2020;1:898–907.
   PubMedGoogle Scholar
• Schnapp BH, Slovis BH, Shah AD, et al. Workplace violence and harassment against emergency medicine residents. West J Emerg Med. 2016;17(5):567–573.
   PubMed Web of Science ®Google Scholar
• American College of Emergency Physicians. ACEP emergency department violence poll research results. https://www.emergencyphysicians.org/globalassets/files/pdfs/2018acep-emergency-department-violence-pollresults-2.pdf. 2018. cited 2022 Oct 2
   Google Scholar
• Richmond JS, Berlin JS, Fishkind AB, et al. Verbal de-escalation of the agitated patient: consensus statement of the American Association for Emergency Psychiatry Project BETA de-escalation workgroup. West J Emerg Med. 2012;13(1):17–25.
   PubMedGoogle Scholar
• Wilson MP, Pepper D, Currier GW, et al., The psychopharmacology of agitation: consensus statement of the American association for emergency psychiatry project Beta psychopharmacology workgroup. West J Emerg Med. 2012;13(1):26–34.
   PubMedGoogle Scholar
• Martínez-Raga J, Amore M, Di Sciascio G, et al. 1st international experts’ meeting on agitation: conclusions regarding the current and ideal management paradigm of agitation. Front Psychiatry. 2018;9:54.
   PubMed Web of Science ®Google Scholar
• Zeller SL, Citrome L. Managing agitation associated with schizophrenia and bipolar disorder in the emergency setting. West J Emerg Med. 2016;17(2):165–172.
   PubMedGoogle Scholar
• Ng AT, Zeller SL, Rhoades RW. Clinical challenges in the pharmacologic management of agitation. Prim Psychiatry. 2010;17:46–52.
   Google Scholar
• Currier GW, Medori R. Orally versus intramuscularly administered antipsychotic drugs in psychiatric emergencies. J Psychiatr Pract. 2006;12(1):30–40.
   PubMedGoogle Scholar
• Lorazepam Tablets [package insert]. Bausch Health Companies Inc; 2022
   Google Scholar
• Lorazepam Injection[package insert]. Hospira; 2022
   Google Scholar
• Faden J, Citrome L. Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Neuropsychiatr Dis Treat. 2019;15:2273–2283.
   PubMed Web of Science ®Google Scholar
• Allam AA, Eleraky NE, Diab NH, et al. Development of sedative dexmedetomidine sublingual in situ gels: in vitro and in vivo evaluations. Pharmaceutics. 2022;14(2):220.
   PubMed Web of Science ®Google Scholar
• Igalmi [package insert]. BioXcel Therapeutics, Inc; 2022
   Google Scholar
• Preskorn SH. How an understanding of the function of the locus coeruleus led to use of dexmedetomidine to treat agitation in bipolar disorder: example of rational development of psychiatric medications. J Psychiatr Pract. 2022;28(3):227–233.
   PubMed Web of Science ®Google Scholar
• Preskorn SH. Treatment of agitation in individuals with bipolar disorder or schizophrenia: lessons learned for clinical psychiatry and psychiatric drug development. J Psychiatr Pract. 2022;28(4):319–323.
   PubMed Web of Science ®Google Scholar
• Bohringer C, Liu H. Is It Time for an Expanded Role of Dexmedetomidine in Contemporary Anesthesia Practice? - A Clinician’s Perspective. Transl Perioper Pain Med. 2018;5(3):55–62.
   PubMedGoogle Scholar
• Weerink MAS, Struys MMRF, Hannivoort LN, et al. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 2017;56(8):893–913.
   PubMed Web of Science ®Google Scholar
• Preskorn SH, Zeller S, Citrome L, et al., Effect of sublingual dexmedetomidine vs placebo on acute agitation associated with bipolar disorder: a randomized clinical trial. JAMA. 2022;327(8):727–736.
   PubMed Web of Science ®Google Scholar
• Citrome L, Preskorn SH, Lauriello J, et al., Sublingual dexmedetomidine for the treatment of acute agitation in adults with schizophrenia or schizoaffective disorder: a randomized placebo-controlled trial. J Clin Psychiatry. 2022;83(6):22m14447.
   PubMedGoogle Scholar
• Sheehan D, Lecrubier Y, Harnett Sheehan K, et al. The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry. 1997;12(5):232–241.
   Web of Science ®Google Scholar
• Montoya A, Valladares A, Lizán L, et al. Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health Qual Life Outcomes. 2011;9(1):18.
   PubMedGoogle Scholar
• Baker RW, Kinon BJ, Maguire GA, et al. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol. 2003;23(4):342–348.
   PubMed Web of Science ®Google Scholar
• Citrome L, Risinger R, Rajachandran L, et al. Sublingual dexmedetomidine for agitation associated with schizophrenia or bipolar disorder: a post hoc analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Adv Ther. 2022;39(10):4821–4835.
   PubMed Web of Science ®Google Scholar
• Citrome L, Preskorn S, Watson C, et al. 2 Dexmedetomidine Sublingual Film for Acute Agitation in Schizophrenia or Bipolar Disorder by Baseline Clinical Global Impression-Severity of Agitation. Ann Emerg Med. 2022;80(4):S1–S2
   PubMedGoogle Scholar
• Miceli JJ, Tensfeldt TG, Shiovitz T, et al. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder. Clin Ther. 2010;32(3):472–491.
   PubMed Web of Science ®Google Scholar
• Kersting XAK, Hirsch S, Steinert ST. Physical harm and death in the context of coercive measures in psychiatric patients: a systematic review. Front Psychiatry. 2019;10:400.
   PubMed Web of Science ®Google Scholar
• Chieze M, Hurst S, Kaiser S, et al. Effects of seclusion and restraint in adult psychiatry: a systematic review. Front Psychiatry. 2019;10:491.
   PubMed Web of Science ®Google Scholar
• Pratts M, Citrome L, Grant W, et al. A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatr Scand. 2014;130(1):61–68.
   PubMed Web of Science ®Google Scholar
• Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry. 2007;68(12):1876–1885.
   PubMed Web of Science ®Google Scholar
• Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature. 2005;437(7063):1257–1263.
   PubMed Web of Science ®Google Scholar
• Tononi G, Cirreli C. The neurobiology of sleep. In: Charney DS, Nestler EJ, editors. Neurobiology of Mental Illness. Third ed. Oxford (UK): Oxford University Press; 2009. p. 1370–1386.
   Google Scholar
• Virtanen R, Savola J-M, Saano V, et al. Characterization of the selectivity, specificity and potency of medetomidine as an α2-adrenoceptor agonist. Eur J Pharmacol. 1988;150(1–2):9–14.
   PubMed Web of Science ®Google Scholar
• Hall JE, Uhrich TD, Barney JA, et al. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg. 2000;90(3):699–705.
   PubMed Web of Science ®Google Scholar
• Citrome L, Ketter TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract. 2013;67(5):407–411.
   PubMed Web of Science ®Google Scholar
• Medlinskiene K, Tomlinson J, Marques I, et al. Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review. BMC Health Serv Res. 2021;21(1):1198.
   PubMed Web of Science ®Google Scholar